From the Journals: Information on Tamoxifen Management

Two papers in the journals of the American Association for Cancer Research this morning provide new information on tamoxifen, a widely used breast cancer treatment.

The first, published in Cancer Research, identified a gene signature that can predict which tumors will respond to tamoxifen and which will not.

The second, published in Clinical Cancer Research, found that a topical gel containing the active ingredient in tamoxifen, 4-OHT, was as effective in reducing cell proliferation as oral tamoxifen in women with ductal carcinoma in situ (DCIS). The gel, which was applied directly to breast skin, also caused fewer side effects.

This research was featured in the Washington Post, Time, and NBC News.

Share this:

Leave a Reply